A short, evidence-grounded conversation about Apigenin and its place in longevity science.
Speaker 1
...and that’s where apigenin comes in. It’s a flavone, and studies show it acts as a CD38 inhibitor.
Speaker 2
So, it helps maintain NAD⁺ levels? That's the big takeaway?
Speaker 1
Precisely. By inhibiting CD38, apigenin effectively slows down the breakdown of NAD⁺, thus helping to preserve its levels in the body. This is a key part of the NAD⁺/Sirtuin axis, a pathway of significant interest in longevity research.
Speaker 2
We've seen some promising cell and animal studies on CD38 inhibition and NAD⁺ preservation. For example, a paper in Nature Metabolism in 2019 really highlighted the potential.
Speaker 1
Yes, fascinating stuff. But it also raises an important question: what don't we know yet about apigenin specifically in humans for this purpose?
Speaker 2
That's the open question, isn't it? While the mechanism of action is fairly well-established – apigenin inhibiting CD38 – we still lack robust, large-scale human trials directly demonstrating its long-term impact on NAD⁺ levels and subsequent health outcomes.
Speaker 1
Exactly. We understand the how it works at a molecular level, but the what it does for human longevity in a measurable way, over time, that's still largely unproven. Are there optimal dosages? Are there specific populations who might benefit more?
Speaker 2
And what about potential side effects or interactions? The current evidence is suggestive, but for now, we're talking about a promising molecule within a complex pathway, not a definitive longevity intervention. More research is definitely needed before we can draw firm conclusions for human application.
Educational research discussion only — not medical advice. Statements have not been
evaluated by the FDA. Nothing here is intended to diagnose, treat, cure or prevent any disease.
Talk to a qualified clinician before changing any treatment.